Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20599223 | 0.75 | RBP4 (0.41) | CYP2C19ALDH1A1MAPK1 | |
| SCHEMBL20614849 | 0.74 | VNN1 (0.34) | — | |
| SCHEMBL20619561 | 0.68 | VNN1 (0.39) | CYP2C19ALDH1A1MAPK1 | |
| SCHEMBL20618190 | 0.67 | ABCC1 (0.37) | ALDH1A1 | |
| SCHEMBL20598365 | 0.67 | KMT2A (0.51) | CYP2C19LMNATSHRALDH1A1 | |
| SCHEMBL19699773 | 0.63 | RBP4 (0.42) | KIF18ALMNAPDE10A | |
| SCHEMBL17674350 | 0.63 | OGA (0.38) | — | |
| SCHEMBL17845850 | 0.63 | VNN1 (0.40) | LMNAALDH1A1 | |
| SCHEMBL20619566 | 0.61 | HSD17B10 (0.42) | KIF18ACYP2C19LMNATSHRALDH1A1 | |
| SCHEMBL20619837 | 0.61 | KIF18A (0.39) | KIF18ACYP2C19TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | KIF18A 3926/4885CYP2C19 26/4885LMNA 2866/4885 |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | KIF18A 3926/4885CYP2C19 26/4885LMNA 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.